Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COMMENTARY
COMMENTARY
- Forecasting the Hypertensives Market: A Look Five Years Ahead Sugio Seko President, Pharma Marketing Survey Research Laboratory
August 11, 2003
-
June 9, 2003
-
May 12, 2003
-
March 24, 2003
-
January 20, 2003
- < Special Contribution >
January 13, 2003
- BARKER ON DRUGS
December 23, 2002
- BARKER ON DRUGS (10)
November 18, 2002
- BARKER ON DRUGS (9)
October 14, 2002
- Commentary 2 articles
October 7, 2002
- Barker on Drugs (8)
September 9, 2002
- Barkers on Drugs (7)
July 29, 2002
- BARKER ON DRUGS (6) Great Results, Shame about the Forecasts
June 24, 2002
- BARKER ON DRUGS(5)
June 3, 2002
- BARKER ON DRUGS(4)
April 22, 2002
- Drastically Changing Marketing Strategy - The Best Strategy for Company Differentiation -
April 22, 2002
- BARKER ON DRUGS (3)
March 11, 2002
- BARKER ON DRUGS
February 18, 2002
- Comarketing as a Marketing Strategy Option -1-
January 21, 2002
- Comarketing as a Marketing Strategy Option -2-
January 21, 2002
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…